CA2553160A1 - 2-heteroaryl-substituted benzimidazole derivative - Google Patents
2-heteroaryl-substituted benzimidazole derivative Download PDFInfo
- Publication number
- CA2553160A1 CA2553160A1 CA002553160A CA2553160A CA2553160A1 CA 2553160 A1 CA2553160 A1 CA 2553160A1 CA 002553160 A CA002553160 A CA 002553160A CA 2553160 A CA2553160 A CA 2553160A CA 2553160 A1 CA2553160 A1 CA 2553160A1
- Authority
- CA
- Canada
- Prior art keywords
- pyridin
- benzimidazole
- yloxy
- phenoxy
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A glucokinase activator; a therapeutic and/or preventive agent for diabetes or a therapeutic and/or preventive agent for complications of diabetes, such as retinopathy, nephropathy, neurosis, ischemic heart disease, and arteriosclerosis; and a therapeutic and/or preventive agent for obesity. The glucokinase activator is characterized by containing either a 2-heteroaryl-substituted benzimidazole derivative represented by the general formula (I-0):
1 RING A (I-0) [wherein X represents carbon or nitrogen; X1, X2, X3, and X4 each independently represents carbon or nitrogen; ring A represents, e.g., a 5-or 6-membered nitrogenous aromatic heterocycle represented by the formula (II): 1 RING A (II) (wherein X represents carbon or nitrogen); R1 represents aryl, etc.; R2 represents hydroxy, etc.; R3 represents -(C1-6 alkyl), etc.; R4 represents -(C1-6 alkyl), etc.; X5 represents -O-, etc.; a is 1, 2, or 3; q is an integer of 0 to 2; and m is an integer of 0 to 2] or a pharmaceutically acceptable salt of the derivative.
1 RING A (I-0) [wherein X represents carbon or nitrogen; X1, X2, X3, and X4 each independently represents carbon or nitrogen; ring A represents, e.g., a 5-or 6-membered nitrogenous aromatic heterocycle represented by the formula (II): 1 RING A (II) (wherein X represents carbon or nitrogen); R1 represents aryl, etc.; R2 represents hydroxy, etc.; R3 represents -(C1-6 alkyl), etc.; R4 represents -(C1-6 alkyl), etc.; X5 represents -O-, etc.; a is 1, 2, or 3; q is an integer of 0 to 2; and m is an integer of 0 to 2] or a pharmaceutically acceptable salt of the derivative.
Claims (23)
1. A compound of a formula (I-0):
or a pharmaceutically acceptable salt thereof, wherein:
X represents a carbon atom or a nitrogen atom;
X1, X2, X3 and X4 each independently represent a carbon atom or a nitrogen atom;
the ring A represents a 5- or 6-membered nitrogen-containing aromatic hetero ring of a formula (II), optionally having, in the ring, from 1 to 3 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom but excepting the nitrogen atom of N*
in formula II:
or represents a twin-ring of the nitrogen-containing aromatic hetero ring condensed with a phenyl or a pyridyl;
R1 represents an aryl, or represents a 4- to 10-membered, monocyclic or twin-cyclic hetero ring having, in the ring, from 1 to 4 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom and R1 may be independently substituted with from 1 to 3 R4's, and when said hetero ring is an aliphatic hetero ring, then it may have 1 or 2 double bonds;
R2 independently represents a hydroxy, a formyl, -CH3-a F a, -OCH3-a F a, an amino, CN, a halogen, a C1-6 alkyl or -(CH2)1-4OH;
R3 represents a -C1-6 alkyl, -(CH2)1-6-OH, a -C(O)-OC1-6 alkyl, a -(CH2)1-6-OC1-6 alkyl, -(CH2)1-6-NH2, a cyano, a -C(O)-C1-6 alkyl, a halogen, a -C2-6 alkenyl, an -OC1-6 alkyl, -COOH, -OH or an oxo;
R4 independently represents a -C1-6 alkyl and the alkyl may be substituted with the same or different, from 1 to 3 hydroxyls, halogens, -OC(O)-C1-6 alkyls and the alkyl may be substituted with from 1 to 3 halogens or -OC1-6 alkyls, a -C3-7 cycloalkyl, a -C2-6 alkenyl, -C(O)-N(R51)R52, -S(O)2-N(R51)R52, an -O-C1-6 alkyl and the C1-6 alkyl may be substituted with a halogen or N(R51)R52, an -S(O)0-2-C1-6 alkyl, a -C(O)-C1-6 alkyl and the C1-6 alkyl may be substituted with a halogen, an amino, CN, a hydroxy, an -O-C1-6 alkyl, -CH3-aFa, an -OC(O)-C1-6 alkyl, an -N(C1-6 alkyl)C(O)O-C1-6 alkyl, an -NH-C(O)O-C1-6 alkyl, a phenyl, -N(R51)R52, an -NH-C(O)-C1-6 alkyl, an -N(C1-6 alkyl)-C(O)-C1-6 alkyl or an -NH-S(O)0-2-C1-6 alkyl, a -C(S)-C3-7 cycloalkyl, a -C(S)-C1-6 alkyl, a -C(O)-O-C1-6 alkyl, -(CH2)0-4-N(R53)-C(O)-R54, -N(R53)-C(O)-O-R54 a -C(O)-aryl optionally substituted with a halogen, a -C(O)-aromatic hetero ring, a -C(O)-aliphatic hetero ring, a hetero ring and the hetero ring may be substituted with a -C1-6 alkyl optionally substituted with a halogen or an -O-C1-6 alkyl, a phenyl optionally substituted with a halogen, a -C1-6 alkyl, an -O-C1-6 alkyl, a halogen, CN, a formyl, COOH, an amino, an oxo, a hydroxy, a hydroxyamidino or a nitro;
R51 and R52 each independently represent a hydrogen atom, a -C1-6 alkyl; or the nitrogen atom, R51 and R52 together form a 4- to 7-membered hetero ring;
R53 represents a hydrogen atom or a -C1-6 alkyl, R54 represents a -C1-6 alkyl, or the alkyls for R53 and R54 and -N-C(O)- together form a 4- to 7-membered nitrogen-containing aliphatic hetero ring, or the alkyls for R53 and R54 and -N-C(O)-O- together form a 4- to 7-membered nitrogen-containing aliphatic hetero ring and the aliphatic hetero ring may be substituted with an oxo, or the aliphatic hetero ring may have 1 or 2 double bonds in the ring;
X5 represents -O-, -S-, -S(O)-, -S(O)2-, a single bond or an -O-C1-6-alkyl;
a independently indicates an integer of 1, 2 or 3;
q indicates an integer of from 0 to 2;
m indicates an integer of from 0 to 2;
excepting a case where one of X5's is -O-, -S-, -S(O)- or -S(O)2-, and the other of X5's is a single bond, and R1 is an aryl optionally substituted with from 1 to 3 R4's, or a nitrogen-containing aromatic hetero ring having from 1 to 4 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom, a case where X5's are both single bonds, or a case where R1's are both aliphatic hetero rings.
or a pharmaceutically acceptable salt thereof, wherein:
X represents a carbon atom or a nitrogen atom;
X1, X2, X3 and X4 each independently represent a carbon atom or a nitrogen atom;
the ring A represents a 5- or 6-membered nitrogen-containing aromatic hetero ring of a formula (II), optionally having, in the ring, from 1 to 3 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom but excepting the nitrogen atom of N*
in formula II:
or represents a twin-ring of the nitrogen-containing aromatic hetero ring condensed with a phenyl or a pyridyl;
R1 represents an aryl, or represents a 4- to 10-membered, monocyclic or twin-cyclic hetero ring having, in the ring, from 1 to 4 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom and R1 may be independently substituted with from 1 to 3 R4's, and when said hetero ring is an aliphatic hetero ring, then it may have 1 or 2 double bonds;
R2 independently represents a hydroxy, a formyl, -CH3-a F a, -OCH3-a F a, an amino, CN, a halogen, a C1-6 alkyl or -(CH2)1-4OH;
R3 represents a -C1-6 alkyl, -(CH2)1-6-OH, a -C(O)-OC1-6 alkyl, a -(CH2)1-6-OC1-6 alkyl, -(CH2)1-6-NH2, a cyano, a -C(O)-C1-6 alkyl, a halogen, a -C2-6 alkenyl, an -OC1-6 alkyl, -COOH, -OH or an oxo;
R4 independently represents a -C1-6 alkyl and the alkyl may be substituted with the same or different, from 1 to 3 hydroxyls, halogens, -OC(O)-C1-6 alkyls and the alkyl may be substituted with from 1 to 3 halogens or -OC1-6 alkyls, a -C3-7 cycloalkyl, a -C2-6 alkenyl, -C(O)-N(R51)R52, -S(O)2-N(R51)R52, an -O-C1-6 alkyl and the C1-6 alkyl may be substituted with a halogen or N(R51)R52, an -S(O)0-2-C1-6 alkyl, a -C(O)-C1-6 alkyl and the C1-6 alkyl may be substituted with a halogen, an amino, CN, a hydroxy, an -O-C1-6 alkyl, -CH3-aFa, an -OC(O)-C1-6 alkyl, an -N(C1-6 alkyl)C(O)O-C1-6 alkyl, an -NH-C(O)O-C1-6 alkyl, a phenyl, -N(R51)R52, an -NH-C(O)-C1-6 alkyl, an -N(C1-6 alkyl)-C(O)-C1-6 alkyl or an -NH-S(O)0-2-C1-6 alkyl, a -C(S)-C3-7 cycloalkyl, a -C(S)-C1-6 alkyl, a -C(O)-O-C1-6 alkyl, -(CH2)0-4-N(R53)-C(O)-R54, -N(R53)-C(O)-O-R54 a -C(O)-aryl optionally substituted with a halogen, a -C(O)-aromatic hetero ring, a -C(O)-aliphatic hetero ring, a hetero ring and the hetero ring may be substituted with a -C1-6 alkyl optionally substituted with a halogen or an -O-C1-6 alkyl, a phenyl optionally substituted with a halogen, a -C1-6 alkyl, an -O-C1-6 alkyl, a halogen, CN, a formyl, COOH, an amino, an oxo, a hydroxy, a hydroxyamidino or a nitro;
R51 and R52 each independently represent a hydrogen atom, a -C1-6 alkyl; or the nitrogen atom, R51 and R52 together form a 4- to 7-membered hetero ring;
R53 represents a hydrogen atom or a -C1-6 alkyl, R54 represents a -C1-6 alkyl, or the alkyls for R53 and R54 and -N-C(O)- together form a 4- to 7-membered nitrogen-containing aliphatic hetero ring, or the alkyls for R53 and R54 and -N-C(O)-O- together form a 4- to 7-membered nitrogen-containing aliphatic hetero ring and the aliphatic hetero ring may be substituted with an oxo, or the aliphatic hetero ring may have 1 or 2 double bonds in the ring;
X5 represents -O-, -S-, -S(O)-, -S(O)2-, a single bond or an -O-C1-6-alkyl;
a independently indicates an integer of 1, 2 or 3;
q indicates an integer of from 0 to 2;
m indicates an integer of from 0 to 2;
excepting a case where one of X5's is -O-, -S-, -S(O)- or -S(O)2-, and the other of X5's is a single bond, and R1 is an aryl optionally substituted with from 1 to 3 R4's, or a nitrogen-containing aromatic hetero ring having from 1 to 4 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom, a case where X5's are both single bonds, or a case where R1's are both aliphatic hetero rings.
2. A compound as claimed in claim l, or a pharmaceutically acceptable salt thereof, wherein X1 to X4, are all carbon atoms.
3. A compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof, wherein X5 is -O-, -S-, -S(O)-, -S(O)2- or a single bond.
4. A compound as claimed in 1, which is represented by a formula (I-1):
(I-1 ) or a pharmaceutically acceptable salt therof, wherein:
R11 represents a phenyl optionally substituted with from 1 to 3 R4's, or represents a 5- or 6-membered nitrogen-containing aromatic hetero ring having from 1 to 4 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom and the nitrogen-containing aromatic hetero ring may be substituted with from 1 to 3 R4's; and X51 represents -O-, -S-, -S(O)- or -S(O)2-; and the other symbols have the same meanings as above.
(I-1 ) or a pharmaceutically acceptable salt therof, wherein:
R11 represents a phenyl optionally substituted with from 1 to 3 R4's, or represents a 5- or 6-membered nitrogen-containing aromatic hetero ring having from 1 to 4 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom and the nitrogen-containing aromatic hetero ring may be substituted with from 1 to 3 R4's; and X51 represents -O-, -S-, -S(O)- or -S(O)2-; and the other symbols have the same meanings as above.
5. A compound as claimed in claim 4, or a pharmaceutically acceptable salt thereof, wherein R11's are both phenyls optionally substituted with from 1 to 3 R4's.
6. A compound as claimed in claim 4,or a pharmaceutically acceptable salt thereof, wherein R11's are both 5- or 6-membered nitrogen-containing aromatic hetero rings having from 1 to 4 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom and the nitrogen-containing aromatic hetero ring may be substituted with from 1 to 3 R4's.
7. A compound as claimed in claim 4, or a pharmaceutically acceptable salt thereof, wherein one of R11's is a phenyl optionally substituted with from 1 to 3 R4's, and the other of R11's is a 5- or 6-membered nitrogen-containing aromatic hetero ring having from 1 to 4 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom and the nitrogen-containing aromatic hetero ring may be substituted with from 1 to 3 R4's.
8. A compound as claimed in claim 1, which is represented by a formula (I-2):
(I-2) or a pharmaceutically acceptable salt thereof, wherein:
R11 represents a phenyl optionally substituted with from 1 to 3 R4's, or represents a 5- or 6-membered nitrogen-containing aromatic hetero ring having from 1 to 4 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom and the nitrogen-containing aromatic hetero ring may be substituted with from 1 to 3 R4's; and R12 represents a 4- to 7-membered nitrogen-containing hetero ring having, as the hetero atom constituting the hetero ring, at least one nitrogen atom and optionally having, as the other hetero atoms, from 1 to 4 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom and R12 may be substituted with from 1 to 3 R4's, and when the hetero ring is an aliphatic hetero ring, then it may have 1 or 2 double bonds;
X51, represents -O-, -S-, -S(O)- or -S(O)2-;
X52 represents -O-, -S-, -S(O)-, -S(O)2- or a single bond; and the other symbols have the same meanings as above.
(I-2) or a pharmaceutically acceptable salt thereof, wherein:
R11 represents a phenyl optionally substituted with from 1 to 3 R4's, or represents a 5- or 6-membered nitrogen-containing aromatic hetero ring having from 1 to 4 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom and the nitrogen-containing aromatic hetero ring may be substituted with from 1 to 3 R4's; and R12 represents a 4- to 7-membered nitrogen-containing hetero ring having, as the hetero atom constituting the hetero ring, at least one nitrogen atom and optionally having, as the other hetero atoms, from 1 to 4 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom and R12 may be substituted with from 1 to 3 R4's, and when the hetero ring is an aliphatic hetero ring, then it may have 1 or 2 double bonds;
X51, represents -O-, -S-, -S(O)- or -S(O)2-;
X52 represents -O-, -S-, -S(O)-, -S(O)2- or a single bond; and the other symbols have the same meanings as above.
9. A compound as claimed in claim 8, or a pharmaceutically acceptable salt thereof, wherein R12 represents a 4- to 7-membered saturated nitrogen-containing aliphatic hetero ring having, as the hetero atom constituting the hetero ring, at least one nitrogen atom and optionally having, as the other hetero atoms, 1 or 2 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom and the nitrogen-containing aliphatic hetero ring may be substituted with from 1 to 3 R4's, and X52 is a single bond; or R12 represents a 5- to 7-membered nitrogen-containing aliphatic hetero ring having, as the atom constituting the hetero ring, at least one nitrogen atom and optionally having, as the other hetero atoms, 1 or 2 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom, and having, in the ring, 1 or 2 double bonds and the 5- to 7-membered hetero ring may be substituted with from 1 to 3 R4's, and X52 is -O-, -S-, -S(O)- or -S(O)2-.
10. A compound as claimed in claim 8, or a pharmaceutically acceptable salt thereof, wherein R12 represents a 4- to 7-membered saturated nitrogen-containing aliphatic hetero ring having, as the hetero atom constituting the hetero ring, at least one nitrogen atom and optionally having, as the other hetero atoms, 1 or 2 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom and the nitrogen-containing aliphatic hetero ring may be substituted with from 1 to 3 R4's, and X52 is a single bond.
11. A compound as claimed in claim 8, or a pharmaceutically acceptable salt thereof, wherein R12 represents a 5- to 7-membered nitrogen-containing aliphatic hetero ring having, as the atom constituting the hetero ring, at least one nitrogen atom and optionally having, as the other hetero atoms, 1 or 2 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom, and having, in the ring, 1 or 2 double bonds and the 5- to 7-membered hetero ring may be substituted with from 1 to 3 R4's, and X52 is -O-, -S-, -S(O)- or -S(O)2-.
12. A compound as claimed in claim 8, or a pharmaceutically acceptable salt thereof, wherein R12 represents a 5- to 7-membered nitrogen-containing aliphatic hetero ring having, as the atom constituting the hetero ring, at least one nitrogen atom and optionally having, as the other hetero atoms, 1 or 2 hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom, and having, in the ring, 1 or 2 double bonds and the nitrogen-containing aliphatic hetero ring may be substituted with from 1 to 3 R4's, and X52 is -O-.
13. A compound as claimed in claim 3, or a pharmaceutically acceptable salt thereof of formula (I-1), which is represented by a formula (I-11):
(I-11) and in the formula, the symbols have the same meanings as above.
(I-11) and in the formula, the symbols have the same meanings as above.
14. A compound as claimed in claim 13, or a pharmaceutically acceptable salt thereof, wherein X51's are both -O-;
15. A compound or a pharmaceutically acceptable salt thereof of formula (I-1) which is represented by a formula (I-12):
(I-12) and in the formula, the symbols have the same meanings as above.
(I-12) and in the formula, the symbols have the same meanings as above.
16. A compound as claimed in claim 15, or a pharmaceutically acceptable salt thereof, wherein X51's are both -O-.
17. A compound as claimed in claim 10, or a pharmaceutically acceptable salt thereof, wherein R12 is represented by a formula (III-1):
or a formula (III-2) and the formulae, n indicates an integer of from 1 to 3; R41 has the same meaning as that of R4.
or a formula (III-2) and the formulae, n indicates an integer of from 1 to 3; R41 has the same meaning as that of R4.
18. A compound as claimed in any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein the ring A is a thiazolyl, an imidazolyl, an isothiazolyl, a thiadiazolyl, an oxadiazolyl, a triazolyl, an oxazolyl, an isoxazolyl, a pyrazinyl, a pyridyl, a pyridazinyl, a pyrazolyl or a pyrimidinyl, which may be substituted with from 1 to 3 R4's.
19. A compound of formula (I-0), which is the following compound:
5-(4-methanesulfonyl-phenoxy)-2-pyrazin-2-yl-6-(2-carbamoyl-phenoxy)-1 H-benzimidazole, 5-(2-carbamoyl-phenoxy)-2-pyridin-2-yl-6-(6-(methanesulfonyl-pyridin-3-yloxy)-benzimidazole, 5-(2-carbamoyl-phenoxy)-2-pyrazin-2-yl-6-(6-methanesulfonyl-pyridin-3-yloxy)-benzimidazole, 5-(2-fluoro-phenoxy)-2-pyridin-2-yl-6-(6-methanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-difluoromethoxy-pyridin-3-yloxy)-6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-1H-benzimidazole, 5-(2-difluoromethoxy-pyridin-3-yloxy)-6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-1H-benzimidazole, 5-(2-difluoromethoxy-pyridin-3-yloxy)-6-(6-methanesulfonyl-pyridin-3-yloxy)-2-(1-methyl-1H-pyrazol-3-yl)-1H-benzimidazole, 5-(2-cyano-phenoxy)-2-pyridin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-fluoro-phenoxy)-2-pyridin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-fluoro-phenoxy)-2-(1H-pyrazol-3-yl)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-benzimidazole, 5-(2,3-difluoro-phenoxy)-2-( 1-methyl-1H-pyrazol-3-yl)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2,4-difluoro-phenoxy)-2-pyrazin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2,5-difluoro-phenoxy)-2-pyridin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2,6-difluoro-phenoxy)-2-pyrazin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2,6-difluoro-phenoxy)-2-(1-methyl-1H-pyrazol-3-yl)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-fluoropyridin-3-yloxy)-6-(6-ethanesulfonylpyridin-3-yloxy)-2-pyridin-2-yl-benzimidazole, 5-(2-fluoropyridin-3-yloxy)-6-(6-ethanesulfonylpyridin-3-yloxy)-2-pyrazin-2-yl-benzimidazole, 5-(2-chloropyridin-3-yloxy)-6-(6-ethanesulfonylpyridin-3-yloxy)-2-pyridin-2-yl-benzimidazole, 5-(2-chloropyridin-3-yloxy)-6-(6-ethanesulfonylpyridin-3-yloxy)-2-pyrazin-2-yl-benzimidazole, 5-(2-cyanopyridin-3-yloxy)-6-(6-ethanesulfonylpyridin-3-yloxy)-2-pyridin-2-yl-benzimidazole, 5-(2-difluoromethoxy-pyridin-3-yloxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-1H-benzimidazole, 5-(2-difluoromethoxy-pyridin-3-yloxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-1 H-benzimidazole, 5-(2-difluoromethoxy-pyridin-3-yloxy)-6-(4-ethanesulfonyl-phenoxy)-2-pyridin-2-yl-1H-benzimidazole, 5-(2-difluoromethoxy-pyridin-3-yloxy)-6-(4-ethanesulfonyl-phenoxy)-2-pyrazin-2-yl-1H-benzimidazole, 5-(2,6-difluoro-phenoxy)-2-pyridin-2-yl-6-(6-methanesulfonyl-pyridin-3-yloxy)-benzimidazole, 5-(2-carbamoyl-phenoxy)-2-pyridin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-fluoro-6-cyano-phenoxy)-2-pyridin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-fluoro-6-carbamoyl-phenoxy)-2-pyridin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1 H-benzimidazole, 5-(2-fluoro-6-carbamoyl-phenoxy)-2-pyrazin-2-yl-6-(4-ethanesulfonyl-phenoxy)-benzimidazole, 5-(2-fluoro-6-cyano-phenoxy)-2-pyrazin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-fluoro-6-(tetrazol-5-yl)-phenoxy)-2-pyrazin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-difluoromethoxypyridin-3-yloxy)-6-(3-chloro-4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-1H-benzimidazole, 4-(2-fluoro-phenoxy)-2-(pyridin-2-yl)-6-(4-methanesulfonyl-phenoxy)-1H-benzimidazole, 4-(2,6-difluoro-phenoxy)-6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-benzimidazole, 4-(2,6-difluoro-phenoxy)-6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-benzimidazole, 4-(2,6-difluoro-phenoxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-1H-benzimidazole, 4-(2,6-difluoro-phenoxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-1H-benzimidazole, 4-(1-methyl-2-oxo-1,2-dihydro-pyridin-3-yloxy)-6-(4-ethanesulfonyl-phenoxy)-2-pyridin-2-yl-1H-benzimidazole, 4-(2,6-difluoro-phenoxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-(1H-pyrazol-3-yl)-1H-benzimidazole, 4-(2-fluoro-phenoxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-1H-benzimidazole, 4-(2,3-difluoro-phenoxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-1H-benzimidazole, 4-(2,5-difluoro-phenoxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-1H-benzimidazole, 4-(2-cyano-6-fluoro-phenoxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-1H-benzimidazole, 4-(2-cyano-6-fluoro-phenoxy)-6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-1H-benzimidazole, 4-(2-cyano-6-fluoro-phenoxy)-6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-1H-benzimidazole, 1-(2-(6-(5-bromo-pyridin-2-yloxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 1-(2-(6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 1-(2-(6-(4-hydroxymethyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 1-(2-(6-(4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 2-(6-(4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidine-1-carboxamide, 2-hydroxy-1-(2-(6-(4-methanesulfonyl-1-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 1-(2-(6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 1-(2-(6-(4-methanesulfonyl-phenoxy)-2-pyrazin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 2-fluoro-1-(2-(6-(4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 5-(6-(1-acetyl-pyrrolidin-2-yl)-2-pyridin-2-yl-1H-benzimidazole-5-yloxy)pyridine-2-carbonitrile, 1-(2-(6-(4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-2-methylamino-ethanone, 1-(2-(6-(4-methanesulfonyl-phenoxy)-2-(1H-pyrazol-3-yl)-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 1-(4-fluoro-2-(6-(4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, N-(5-(6-(1-acetyl-pyrrolidin-2-yl)-2-pyridin-2-yl-1H-benzimidazol-5-yloxy)-pyridin-2-yl)-acetamide, 1-(2-(2-(5-bromo-pyridin-2-yl)-6-(4-methanesulfonyl-phenoxy)-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, N-(2-(2-(6-(4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)pyrrolidin-1-yl)-2-oxo-ethyl)-acetamide, 6-(1-acetylpyrrolidin-2-yl)-5-(4-(methoxymethyl)phenoxy)-2-pyridin-2-y1-1H-benzimidazol monotrifluoroacetate, 1-(4-((6-(1-acetylpyrrolidin-2-yl)-2-pyridin-2-yl-1H-benzimidazol-5-yl)oxy)phenyl)pyridin-2(1H)-one, 6-(1-acetylpyrrolidin-2-yl)-5-((6-(5-methyl-[1,2,4]-oxadiazol-3-yl)pyridin-3-yl)oxy)-2-pyridin-2-yl-1H-benzimidazole, (2-(2-(5-((2'-fluorobiphenyl-4-yl)oxy)-2-pyridin-2-yl-1H-benzimidazol-6-yl)pyrrolidin-1-y1)-2-oxoethyl)methylamine, 6-(1-acetylpyrrolidin-2-yl)-5-((6-([1,2,4]-oxadiazol-3-yl)pyridin-3-yl)oxy)-2-pyridin-2-yl-1H-benzimidazole, 6-(1-acetylpyrrolidin-2-yl)-5-(4-(2-methyl-2H-tetrazol-5-yl)phenoxy)-2-pyrazin-2-yl-1H-benzimidazole, 5-(1-acetyl-3-fluoropyrrolidin-2-yl)-6-(4-(methanesulfonyl)phenoxy)-2-pyridin-2-yl-1H-benzimidazole, 6-(1-acetylpyrrolidin-2-yl)-5-((6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)oxy)-2-pyridin-2-yl-1H-benzimidazole, 6-(1-acetylpyrrolidin-2-yl)-5-(4-(2-methyl-2H-tetrazol-5-yl)phenoxy)-2-pyridin-2-yl-1H-benzimidazole, 5-(1-acetyl-5-methylpyrrolidin-2-yl)-6-(4-(methanesulfonyl)phenoxy)-2-pyridin-2-yl-1H-benzimidazole, 6-(1-acetylpyrrolidin-2-yl)-5-((6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)oxy)-2-pyrazin-2-yl-1H-benzimidazole, 6-(1-acetylpyrrolidin-2-yl)-5-(6-methoxymethylpyridin-3-yl)oxy)-2-pyridin-2-yl-benzimidazole, 2-(2-(5-(4-(2-methyl-2H-tetrazol-5-yl)phenoxy)-2-pyridin-2-yl-1H-benzimidazol-6-yl)pyrrolidin-1-yl)-2-oxoethanol, 2-(5-(4-(2-methyl-2H-tetrazol-5-yl)phenoxy)-2-pyridin-2-yl-1H-benzimidazol-6-yl)pyrrolidine-1-carboxamide, 5'-((6-(1-acetylpyrrolidin-2-yl)-2-pyridin-2-yl-1H-benzimidazol-5-yl)oxy)-2H-1,2'-bipyridin-2-one, 3-(4-((6-(1-acetylpyrrolidin-2-yl)-2-pyridin-2-yl-1H-benzimidazol-5-yl)oxy)phenyl)-1,3-oxazolidin-2-one, 6-(1-acetylpyrrolidin-2-yl)-5-((6-methylpyridin-3-yl)oxy)-2-pyridin-2-yl-1H-benzimidazole, 6-(1-acetylpyrrolidin-2-yl)-5-((6-pyrazin-2-ylpyridin-3-yl)oxy)-2-pyridin-2-yl-1H-benzimidazole, 6-(1-acetyl-3-fluoropyrrolidin-2-yl)-5-((2'-fluorobiphenyl-4-yl)oxy)-2-pyridin-2-yl-1H-benzimidazole, 3-(4-((6-(1-acetylpyrrolidin-2-yl)-2-pyrazin-2-yl-1H-benzimidazol-5-yl)oxy)phenyl)-1,3-oxazolidine-2-one, 6-(1-acetylpyrrolidin-2-yl)-2-pyrazin-2-yl-5-((6-pyrazin-2-ylpyridin-3-yl)oxy)-1H-benzimidazole, 6-(1-acetylpyrrolidin-2-yl)-5-((6-(5-methyl-[1,2,4]-oxadiazol-3-yl)pyridin-3-y1)oxy)-2-pyrazin-2-yl-1H-benzimidazole, 1-(4-((6-(1-acetylpyrrolidin-2-yl)-2-pyrazin-2-yl-1H-benzimidazol-5-yl)oxy)phenyl)ethanone, 6-(1-acetylpyrrolidin-2-yl)-5-(4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenoxy)-2-pyrazin-2-yl-1H-benzimidazole, 6-(1-acetyl-5-methylpyrrolidin-2-yl)-5-(4-methanesulfonyl-phenoxy)-2-pyrazin-2-yl-1H-benzimidazole, N-methyl-2-(2-(5-(4-(2-methyl-2H-tetrazol-5-yl)phenoxy)-2-pyridin-2-yl-1H-benzimidazol-6-yl)pyrrolidin-1-yl)-2-oxoethanamine, 6-(1-acetyl-5-methylpyrrolidin-2-yl)-5-((6-(methoxymethyl)pyridin-3-yl)oxy)-2-pyrazin-2-yl-1H-benzimidazole, 1-(1-(6-(4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-2-yl)-ethanone, 1-(1-(6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)pyrrolidin-2-yl)-ethanone, 1-(1-(6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-3H-benzimidazol-5-yl)pyrrolidin-2-yl)ethanone, or 1-(1-(6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-3H-benzimidazol-5-yl)-4-fluoro-pyrrolidin-2-yl)-ethanone, or a pharmaceutically acceptable salt thereof.
5-(4-methanesulfonyl-phenoxy)-2-pyrazin-2-yl-6-(2-carbamoyl-phenoxy)-1 H-benzimidazole, 5-(2-carbamoyl-phenoxy)-2-pyridin-2-yl-6-(6-(methanesulfonyl-pyridin-3-yloxy)-benzimidazole, 5-(2-carbamoyl-phenoxy)-2-pyrazin-2-yl-6-(6-methanesulfonyl-pyridin-3-yloxy)-benzimidazole, 5-(2-fluoro-phenoxy)-2-pyridin-2-yl-6-(6-methanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-difluoromethoxy-pyridin-3-yloxy)-6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-1H-benzimidazole, 5-(2-difluoromethoxy-pyridin-3-yloxy)-6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-1H-benzimidazole, 5-(2-difluoromethoxy-pyridin-3-yloxy)-6-(6-methanesulfonyl-pyridin-3-yloxy)-2-(1-methyl-1H-pyrazol-3-yl)-1H-benzimidazole, 5-(2-cyano-phenoxy)-2-pyridin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-fluoro-phenoxy)-2-pyridin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-fluoro-phenoxy)-2-(1H-pyrazol-3-yl)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-benzimidazole, 5-(2,3-difluoro-phenoxy)-2-( 1-methyl-1H-pyrazol-3-yl)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2,4-difluoro-phenoxy)-2-pyrazin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2,5-difluoro-phenoxy)-2-pyridin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2,6-difluoro-phenoxy)-2-pyrazin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2,6-difluoro-phenoxy)-2-(1-methyl-1H-pyrazol-3-yl)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-fluoropyridin-3-yloxy)-6-(6-ethanesulfonylpyridin-3-yloxy)-2-pyridin-2-yl-benzimidazole, 5-(2-fluoropyridin-3-yloxy)-6-(6-ethanesulfonylpyridin-3-yloxy)-2-pyrazin-2-yl-benzimidazole, 5-(2-chloropyridin-3-yloxy)-6-(6-ethanesulfonylpyridin-3-yloxy)-2-pyridin-2-yl-benzimidazole, 5-(2-chloropyridin-3-yloxy)-6-(6-ethanesulfonylpyridin-3-yloxy)-2-pyrazin-2-yl-benzimidazole, 5-(2-cyanopyridin-3-yloxy)-6-(6-ethanesulfonylpyridin-3-yloxy)-2-pyridin-2-yl-benzimidazole, 5-(2-difluoromethoxy-pyridin-3-yloxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-1H-benzimidazole, 5-(2-difluoromethoxy-pyridin-3-yloxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-1 H-benzimidazole, 5-(2-difluoromethoxy-pyridin-3-yloxy)-6-(4-ethanesulfonyl-phenoxy)-2-pyridin-2-yl-1H-benzimidazole, 5-(2-difluoromethoxy-pyridin-3-yloxy)-6-(4-ethanesulfonyl-phenoxy)-2-pyrazin-2-yl-1H-benzimidazole, 5-(2,6-difluoro-phenoxy)-2-pyridin-2-yl-6-(6-methanesulfonyl-pyridin-3-yloxy)-benzimidazole, 5-(2-carbamoyl-phenoxy)-2-pyridin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-fluoro-6-cyano-phenoxy)-2-pyridin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-fluoro-6-carbamoyl-phenoxy)-2-pyridin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1 H-benzimidazole, 5-(2-fluoro-6-carbamoyl-phenoxy)-2-pyrazin-2-yl-6-(4-ethanesulfonyl-phenoxy)-benzimidazole, 5-(2-fluoro-6-cyano-phenoxy)-2-pyrazin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-fluoro-6-(tetrazol-5-yl)-phenoxy)-2-pyrazin-2-yl-6-(6-ethanesulfonyl-pyridin-3-yloxy)-1H-benzimidazole, 5-(2-difluoromethoxypyridin-3-yloxy)-6-(3-chloro-4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-1H-benzimidazole, 4-(2-fluoro-phenoxy)-2-(pyridin-2-yl)-6-(4-methanesulfonyl-phenoxy)-1H-benzimidazole, 4-(2,6-difluoro-phenoxy)-6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-benzimidazole, 4-(2,6-difluoro-phenoxy)-6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-benzimidazole, 4-(2,6-difluoro-phenoxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-1H-benzimidazole, 4-(2,6-difluoro-phenoxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-1H-benzimidazole, 4-(1-methyl-2-oxo-1,2-dihydro-pyridin-3-yloxy)-6-(4-ethanesulfonyl-phenoxy)-2-pyridin-2-yl-1H-benzimidazole, 4-(2,6-difluoro-phenoxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-(1H-pyrazol-3-yl)-1H-benzimidazole, 4-(2-fluoro-phenoxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-1H-benzimidazole, 4-(2,3-difluoro-phenoxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-1H-benzimidazole, 4-(2,5-difluoro-phenoxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-1H-benzimidazole, 4-(2-cyano-6-fluoro-phenoxy)-6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-1H-benzimidazole, 4-(2-cyano-6-fluoro-phenoxy)-6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-1H-benzimidazole, 4-(2-cyano-6-fluoro-phenoxy)-6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-1H-benzimidazole, 1-(2-(6-(5-bromo-pyridin-2-yloxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 1-(2-(6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 1-(2-(6-(4-hydroxymethyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 1-(2-(6-(4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 2-(6-(4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidine-1-carboxamide, 2-hydroxy-1-(2-(6-(4-methanesulfonyl-1-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 1-(2-(6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 1-(2-(6-(4-methanesulfonyl-phenoxy)-2-pyrazin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 2-fluoro-1-(2-(6-(4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 5-(6-(1-acetyl-pyrrolidin-2-yl)-2-pyridin-2-yl-1H-benzimidazole-5-yloxy)pyridine-2-carbonitrile, 1-(2-(6-(4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-2-methylamino-ethanone, 1-(2-(6-(4-methanesulfonyl-phenoxy)-2-(1H-pyrazol-3-yl)-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, 1-(4-fluoro-2-(6-(4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, N-(5-(6-(1-acetyl-pyrrolidin-2-yl)-2-pyridin-2-yl-1H-benzimidazol-5-yloxy)-pyridin-2-yl)-acetamide, 1-(2-(2-(5-bromo-pyridin-2-yl)-6-(4-methanesulfonyl-phenoxy)-3H-benzimidazol-5-yl)-pyrrolidin-1-yl)-ethanone, N-(2-(2-(6-(4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)pyrrolidin-1-yl)-2-oxo-ethyl)-acetamide, 6-(1-acetylpyrrolidin-2-yl)-5-(4-(methoxymethyl)phenoxy)-2-pyridin-2-y1-1H-benzimidazol monotrifluoroacetate, 1-(4-((6-(1-acetylpyrrolidin-2-yl)-2-pyridin-2-yl-1H-benzimidazol-5-yl)oxy)phenyl)pyridin-2(1H)-one, 6-(1-acetylpyrrolidin-2-yl)-5-((6-(5-methyl-[1,2,4]-oxadiazol-3-yl)pyridin-3-yl)oxy)-2-pyridin-2-yl-1H-benzimidazole, (2-(2-(5-((2'-fluorobiphenyl-4-yl)oxy)-2-pyridin-2-yl-1H-benzimidazol-6-yl)pyrrolidin-1-y1)-2-oxoethyl)methylamine, 6-(1-acetylpyrrolidin-2-yl)-5-((6-([1,2,4]-oxadiazol-3-yl)pyridin-3-yl)oxy)-2-pyridin-2-yl-1H-benzimidazole, 6-(1-acetylpyrrolidin-2-yl)-5-(4-(2-methyl-2H-tetrazol-5-yl)phenoxy)-2-pyrazin-2-yl-1H-benzimidazole, 5-(1-acetyl-3-fluoropyrrolidin-2-yl)-6-(4-(methanesulfonyl)phenoxy)-2-pyridin-2-yl-1H-benzimidazole, 6-(1-acetylpyrrolidin-2-yl)-5-((6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)oxy)-2-pyridin-2-yl-1H-benzimidazole, 6-(1-acetylpyrrolidin-2-yl)-5-(4-(2-methyl-2H-tetrazol-5-yl)phenoxy)-2-pyridin-2-yl-1H-benzimidazole, 5-(1-acetyl-5-methylpyrrolidin-2-yl)-6-(4-(methanesulfonyl)phenoxy)-2-pyridin-2-yl-1H-benzimidazole, 6-(1-acetylpyrrolidin-2-yl)-5-((6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)oxy)-2-pyrazin-2-yl-1H-benzimidazole, 6-(1-acetylpyrrolidin-2-yl)-5-(6-methoxymethylpyridin-3-yl)oxy)-2-pyridin-2-yl-benzimidazole, 2-(2-(5-(4-(2-methyl-2H-tetrazol-5-yl)phenoxy)-2-pyridin-2-yl-1H-benzimidazol-6-yl)pyrrolidin-1-yl)-2-oxoethanol, 2-(5-(4-(2-methyl-2H-tetrazol-5-yl)phenoxy)-2-pyridin-2-yl-1H-benzimidazol-6-yl)pyrrolidine-1-carboxamide, 5'-((6-(1-acetylpyrrolidin-2-yl)-2-pyridin-2-yl-1H-benzimidazol-5-yl)oxy)-2H-1,2'-bipyridin-2-one, 3-(4-((6-(1-acetylpyrrolidin-2-yl)-2-pyridin-2-yl-1H-benzimidazol-5-yl)oxy)phenyl)-1,3-oxazolidin-2-one, 6-(1-acetylpyrrolidin-2-yl)-5-((6-methylpyridin-3-yl)oxy)-2-pyridin-2-yl-1H-benzimidazole, 6-(1-acetylpyrrolidin-2-yl)-5-((6-pyrazin-2-ylpyridin-3-yl)oxy)-2-pyridin-2-yl-1H-benzimidazole, 6-(1-acetyl-3-fluoropyrrolidin-2-yl)-5-((2'-fluorobiphenyl-4-yl)oxy)-2-pyridin-2-yl-1H-benzimidazole, 3-(4-((6-(1-acetylpyrrolidin-2-yl)-2-pyrazin-2-yl-1H-benzimidazol-5-yl)oxy)phenyl)-1,3-oxazolidine-2-one, 6-(1-acetylpyrrolidin-2-yl)-2-pyrazin-2-yl-5-((6-pyrazin-2-ylpyridin-3-yl)oxy)-1H-benzimidazole, 6-(1-acetylpyrrolidin-2-yl)-5-((6-(5-methyl-[1,2,4]-oxadiazol-3-yl)pyridin-3-y1)oxy)-2-pyrazin-2-yl-1H-benzimidazole, 1-(4-((6-(1-acetylpyrrolidin-2-yl)-2-pyrazin-2-yl-1H-benzimidazol-5-yl)oxy)phenyl)ethanone, 6-(1-acetylpyrrolidin-2-yl)-5-(4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenoxy)-2-pyrazin-2-yl-1H-benzimidazole, 6-(1-acetyl-5-methylpyrrolidin-2-yl)-5-(4-methanesulfonyl-phenoxy)-2-pyrazin-2-yl-1H-benzimidazole, N-methyl-2-(2-(5-(4-(2-methyl-2H-tetrazol-5-yl)phenoxy)-2-pyridin-2-yl-1H-benzimidazol-6-yl)pyrrolidin-1-yl)-2-oxoethanamine, 6-(1-acetyl-5-methylpyrrolidin-2-yl)-5-((6-(methoxymethyl)pyridin-3-yl)oxy)-2-pyrazin-2-yl-1H-benzimidazole, 1-(1-(6-(4-methanesulfonyl-phenoxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)-pyrrolidin-2-yl)-ethanone, 1-(1-(6-(6-methanesulfonyl-pyridin-3-yloxy)-2-pyridin-2-yl-3H-benzimidazol-5-yl)pyrrolidin-2-yl)-ethanone, 1-(1-(6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-3H-benzimidazol-5-yl)pyrrolidin-2-yl)ethanone, or 1-(1-(6-(6-ethanesulfonyl-pyridin-3-yloxy)-2-pyrazin-2-yl-3H-benzimidazol-5-yl)-4-fluoro-pyrrolidin-2-yl)-ethanone, or a pharmaceutically acceptable salt thereof.
20. Apharmaceutical composition comprising the following (1) to (3), which is used for remedy, prevention and/or retardation of onset of type-II diabetes:
(1) a compound stated in any one of claims 1 to 19, (2) one or more compounds selected from the following groups (a) to (h):
(a) any other glucokinase activator, (b) a bis-guanide, (c) a PPAR agonist, (d) an insulin, (e) a somatostatin, (f) an a-glucosidase inhibitor, (g) an insulin, and (h) a DPP-IV (dipeptidyl peptidase IV) inhibitor, (3) a pharmaceutically-acceptable carrier.
(1) a compound stated in any one of claims 1 to 19, (2) one or more compounds selected from the following groups (a) to (h):
(a) any other glucokinase activator, (b) a bis-guanide, (c) a PPAR agonist, (d) an insulin, (e) a somatostatin, (f) an a-glucosidase inhibitor, (g) an insulin, and (h) a DPP-IV (dipeptidyl peptidase IV) inhibitor, (3) a pharmaceutically-acceptable carrier.
21. A glucokinase activator comprising a compound or its pharmaceutically-acceptable salt stated in any one of claims 1 to 19, as the active ingredient thereof;
22. A medicine for remedy and/or prevention of diabetes, comprising a compound or its pharmaceutically-acceptable salt stated in any one of claims 1 to 20, as the active ingredient thereof.
23. A medicine for remedy and/or preventive of obesity, comprising a compound or its pharmaceutically-acceptable salt stated in any one claims 1 to 20, as the active ingredient thereof.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003-436992 | 2003-12-29 | ||
| JP2003436992 | 2003-12-29 | ||
| JP2004-235696 | 2004-08-13 | ||
| JP2004235696 | 2004-08-13 | ||
| PCT/JP2004/019843 WO2005063738A1 (en) | 2003-12-29 | 2004-12-28 | Novel 2-heteroaryl-substituted benzimidazole derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2553160A1 true CA2553160A1 (en) | 2005-07-14 |
| CA2553160C CA2553160C (en) | 2010-09-28 |
Family
ID=34742165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2553160A Expired - Fee Related CA2553160C (en) | 2003-12-29 | 2004-12-28 | 2-heteroaryl-substituted benzimidazole derivative |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7728025B2 (en) |
| EP (1) | EP1702919B1 (en) |
| JP (1) | JP4707560B2 (en) |
| KR (1) | KR20060105872A (en) |
| AU (1) | AU2004309287B2 (en) |
| BR (1) | BRPI0418212A (en) |
| CA (1) | CA2553160C (en) |
| EC (1) | ECSP066682A (en) |
| IL (1) | IL176451A0 (en) |
| IS (1) | IS8509A (en) |
| MA (1) | MA28336A1 (en) |
| NO (1) | NO20063475L (en) |
| NZ (1) | NZ548128A (en) |
| RU (1) | RU2329261C2 (en) |
| WO (1) | WO2005063738A1 (en) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (en) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (en) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| EP1802570A1 (en) | 2004-10-16 | 2007-07-04 | AstraZeneca AB | Process for making phenoxy benzamide compounds |
| CN101094847B (en) * | 2004-11-02 | 2011-06-15 | Msdk.K.公司 | Aryloxy-substituted benzimidazole derivatives |
| TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| AU2006268406C1 (en) | 2005-07-09 | 2011-02-24 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| CA2614544C (en) | 2005-07-13 | 2013-09-10 | Banyu Pharmaceutical Co., Ltd. | Heterocycle-substituted benzimidazole derivative |
| JP2007063225A (en) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | Imidazopyridine compound |
| JP2009508832A (en) * | 2005-09-16 | 2009-03-05 | アストラゼネカ アクチボラグ | Heterobicyclic compounds as glucokinase activators |
| EP1931337B1 (en) | 2005-09-29 | 2013-10-23 | Sanofi | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| EP1948614A2 (en) * | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
| TW200738621A (en) | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
| EP2305640A3 (en) * | 2005-12-15 | 2011-07-20 | AstraZeneca AB | Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases |
| US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| GEP20125643B (en) * | 2006-01-23 | 2012-09-25 | Amgen Inc | Aurora kinase modulators and method of using same |
| LT2010528T (en) | 2006-04-19 | 2017-12-27 | Novartis Ag | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
| PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| TW200825063A (en) | 2006-10-23 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| SA07280576B1 (en) | 2006-10-26 | 2011-06-22 | استرازينيكا ايه بي | Benzoyl amino heterocyclyl compounds as glucokinase (GLK) activators |
| EP2121666A1 (en) | 2006-12-21 | 2009-11-25 | AstraZeneca AB | Novel crystalline compound useful as glk activator |
| US8318746B2 (en) * | 2007-04-27 | 2012-11-27 | Takeda Pharmaceutical Company Limited | Nitrogen-containing five-membered heterocyclic compound |
| AU2008321959B2 (en) | 2007-11-12 | 2014-02-13 | Msd K.K. | Heteroaryloxy quinazoline derivative |
| RU2470917C2 (en) * | 2008-02-06 | 2012-12-27 | Дайити Санкио Компани, Лимитед | Novel phenyl pyrrole derivative |
| DK2294066T3 (en) | 2008-04-28 | 2014-09-08 | Janssen Pharmaceutica Nv | Benzoimidazoles as Prolyl Hydroxylase Inhibitors |
| PE20110568A1 (en) | 2008-08-04 | 2011-09-07 | Astrazeneca Ab | THERAPEUTIC AGENTS 414 |
| CA2733646A1 (en) * | 2008-08-15 | 2010-02-18 | Banyu Pharmaceutical Co., Ltd. | Acetyl pyrrolidinyl indole derivative |
| EP2328892B1 (en) * | 2008-08-29 | 2013-01-16 | Msd K.K. | Oxotetrahydrofuran-2-yl-benzimidazole derivative |
| CA2738429C (en) * | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| GB0902406D0 (en) | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
| GB0902434D0 (en) | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
| AR076221A1 (en) * | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | DERIVED FROM PIRAZOL [4,5-E] PYRIMIDINE AND ITS USE TO TREAT DIABETES AND OBESITY |
| AR076220A1 (en) | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | DERIVATIVES OF PIRAZOL [4,5 - E] PYRIMIDINE |
| UY32799A (en) | 2009-07-24 | 2011-02-28 | Novartis Ag | DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS |
| MX2012005248A (en) | 2009-11-06 | 2012-06-14 | Univ Vanderbilt | Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction. |
| WO2011068211A1 (en) * | 2009-12-04 | 2011-06-09 | 大正製薬株式会社 | 2-pyridone compounds |
| SG181797A1 (en) | 2009-12-18 | 2012-07-30 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| PE20121640A1 (en) | 2009-12-31 | 2012-12-17 | Novartis Ag | PIRAZINE DERIVATIVES AS BACE INHIBITORS |
| WO2012006953A1 (en) | 2010-07-13 | 2012-01-19 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| CN103429589A (en) | 2011-01-12 | 2013-12-04 | 诺瓦提斯公司 | Oxazine derivatives and their use in the treatment of neurological disorders |
| IN2014DN03155A (en) | 2011-10-25 | 2015-05-22 | Janssen Pharmaceutica Nv | |
| HRP20201701T8 (en) * | 2013-09-09 | 2022-01-07 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
| US10807948B2 (en) | 2015-03-11 | 2020-10-20 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
| US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
| WO2016145032A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
| EP3268362B1 (en) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
| US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| MX2018005342A (en) | 2015-11-02 | 2018-08-15 | Janseen Pharmaceutica Nv | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND. |
| EP3535269B1 (en) | 2016-11-02 | 2020-12-09 | Janssen Pharmaceutica NV | [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors |
| CA3041412A1 (en) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
| JP7018944B2 (en) | 2016-11-02 | 2022-02-14 | ヤンセン ファーマシューティカ エヌ．ベー． | [1,2,4] triazolo [1,5-a] pyrimidine compound as a PDE2 inhibitor |
| CA3226162A1 (en) | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL134354C (en) * | 1963-05-23 | |||
| US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| EP0726260A1 (en) | 1995-02-08 | 1996-08-14 | American Cyanamid Company | Herbicidal (1,2,4)thiadiazoles |
| PE92198A1 (en) * | 1996-08-01 | 1999-01-09 | Banyu Pharma Co Ltd | DERIVATIVES OF FLUORINE-CONTAINED 1,4-PIPERIDINE |
| CA2318969A1 (en) * | 1998-01-23 | 1999-07-29 | Mikhail F. Gordeev | Oxazolidinone combinatorial libraries, compositions and methods of preparation |
| JP2000026430A (en) * | 1998-07-02 | 2000-01-25 | Taisho Pharmaceut Co Ltd | 2,5,6-substituted benzimidazole compound derivative |
| WO2003004488A1 (en) * | 2001-07-03 | 2003-01-16 | Chiron Corporation | Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| DE10238002A1 (en) * | 2002-08-20 | 2004-03-04 | Merck Patent Gmbh | benzimidazole derivatives |
| AU2004220234C1 (en) * | 2003-02-13 | 2013-01-17 | Msd K.K. | Novel 2-pyridinecarboxamide derivatives |
| EP1600442B1 (en) * | 2003-02-26 | 2018-01-17 | Msd K.K. | Heteroarylcarbamoylbenzene derivative |
| CN101094847B (en) * | 2004-11-02 | 2011-06-15 | Msdk.K.公司 | Aryloxy-substituted benzimidazole derivatives |
| TW200745031A (en) * | 2005-10-13 | 2007-12-16 | Merck & Co Inc | Acyl indoles, compositions containing such compounds and methods of use |
| TW200821284A (en) * | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
-
2004
- 2004-12-28 BR BRPI0418212-0A patent/BRPI0418212A/en not_active IP Right Cessation
- 2004-12-28 KR KR1020067013089A patent/KR20060105872A/en not_active Application Discontinuation
- 2004-12-28 RU RU2006127420/04A patent/RU2329261C2/en not_active IP Right Cessation
- 2004-12-28 EP EP04808192A patent/EP1702919B1/en active Active
- 2004-12-28 NZ NZ548128A patent/NZ548128A/en unknown
- 2004-12-28 AU AU2004309287A patent/AU2004309287B2/en not_active Ceased
- 2004-12-28 WO PCT/JP2004/019843 patent/WO2005063738A1/en active Application Filing
- 2004-12-28 US US10/582,564 patent/US7728025B2/en active Active
- 2004-12-28 JP JP2005516745A patent/JP4707560B2/en not_active Expired - Fee Related
- 2004-12-28 CA CA2553160A patent/CA2553160C/en not_active Expired - Fee Related
-
2006
- 2006-06-15 IS IS8509A patent/IS8509A/en unknown
- 2006-06-20 IL IL176451A patent/IL176451A0/en unknown
- 2006-06-28 EC EC2006006682A patent/ECSP066682A/en unknown
- 2006-07-27 MA MA29214A patent/MA28336A1/en unknown
- 2006-07-28 NO NO20063475A patent/NO20063475L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1702919B1 (en) | 2012-05-30 |
| MA28336A1 (en) | 2006-12-01 |
| RU2006127420A (en) | 2008-02-10 |
| JPWO2005063738A1 (en) | 2007-07-19 |
| AU2004309287B2 (en) | 2008-07-31 |
| NO20063475L (en) | 2006-09-28 |
| CA2553160C (en) | 2010-09-28 |
| BRPI0418212A (en) | 2007-04-27 |
| US20080070928A1 (en) | 2008-03-20 |
| EP1702919A1 (en) | 2006-09-20 |
| ECSP066682A (en) | 2006-10-25 |
| US7728025B2 (en) | 2010-06-01 |
| EP1702919A4 (en) | 2008-11-12 |
| RU2329261C2 (en) | 2008-07-20 |
| AU2004309287A1 (en) | 2005-07-14 |
| IL176451A0 (en) | 2006-10-05 |
| NZ548128A (en) | 2010-05-28 |
| JP4707560B2 (en) | 2011-06-22 |
| KR20060105872A (en) | 2006-10-11 |
| WO2005063738A1 (en) | 2005-07-14 |
| IS8509A (en) | 2006-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2553160A1 (en) | 2-heteroaryl-substituted benzimidazole derivative | |
| CA2586056C (en) | Aryloxy-substituted benzimidazole derivative | |
| TWI358409B (en) | Heteroaryl substituted piperidine derivatives | |
| JP2019524705A5 (en) | ||
| HRP20161011T1 (en) | Aryl dihydropyridinones and piperidinones as mgat2 inhibitors | |
| IL303196A (en) | Heteroaryl substituted pyridines and methods of use | |
| JP2005517006A5 (en) | ||
| CA2575081A1 (en) | Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses | |
| HRP20170506T1 (en) | Dihydropyridone p1 as factor xia inhibitors | |
| BRPI0711538A2 (en) | pharmaceutical compounds | |
| JP2006518763A5 (en) | ||
| PE20060729A1 (en) | HETEROCYCLIC COMPOUNDS AS MODULATORS OR INHIBITORS OF MYOSTATIN ACTIVITY | |
| CA2566896A1 (en) | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents for modulating effects of histamine-3 receptor | |
| JP2010513272A5 (en) | ||
| RU2016108753A (en) | ENZYME INHIBITORS | |
| RU2008110949A (en) | COMPOUNDS AND COMPOSITIONS-IMMUNOSUPRESSANTS | |
| BRPI0613859A2 (en) | nitrocathecol derivatives, their use and preparation process, as well as pharmaceutical composition | |
| JP2010515734A5 (en) | ||
| JP2011503166A5 (en) | ||
| RU2009111113A (en) | MEDULATORS MGLUR5 | |
| JP2014198727A (en) | Pde10 inhibitor and related composition and method | |
| JP2015509510A5 (en) | ||
| EP2350059A2 (en) | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| RU2018138047A (en) | HETEROCYCLIC SUBSTANCES - AGONISTS GPR119 | |
| RU2014111321A (en) | HYDRAZIDES OF 3-pyridinecarboxylic acids as agents that increase the content of high density lipoprotein cholesterol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |